Brean Murray initiates coverage on Poniard Pharmaceuticals, Inc. (Nasdaq: PARD) with a Buy rating and $11 price target.

The ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE